At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
bimekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating bimekizumab for Moderate to Severe Plaque Psoriasis. Completed, enrolled 41 participants across 11 sites in 4 countries.
Detailed Summary
The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Plaque Psoriasis
CountriesCanada, Germany, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartApr 2021
Primary CompletionMar 2025
TodayJul 2026
First PostedJan 22, 2021
Enrollment StartApr 6, 2021
Primary CompletionMar 12, 2025
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 5.4 years ago
Interventions
bimekizumabdrug
Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.